JO
EGRX

John Overdeck’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

John Overdeck’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-119,312
Closed -$445K – 3585
2024
Q3 		$445K Sell
119,312
-14,632
-11% -$69.8K ﹤0.01% 2524
2024
Q2 		$750K Sell
133,944
-29,491
-18% -$128K ﹤0.01% 2151
2024
Q1 		$856K Sell
163,435
-44,179
-21% -$242K ﹤0.01% 2049
2023
Q4 		$1.09M Buy
207,614
+174,934
+535% +$1.73M ﹤0.01% 2025
2023
Q3 		$515K Buy
32,680
+3,576
+12% +$64.2K ﹤0.01% 2264
2023
Q2 		$566K Buy
+29,104
New +$690K ﹤0.01% 2280
2021
Q2 		– Sell
-127,206
Closed -$5.31M – 4682
2021
Q1 		$5.31M Buy
127,206
+21,524
+20% +$999K 0.01% 1006
2020
Q4 		$4.92M Buy
105,682
+53,409
+102% +$2.5M 0.01% 943
2020
Q3 		$2.22M Buy
52,273
+17,509
+50% +$766K 0.01% 1233
2020
Q2 		$1.67M Buy
+34,764
New +$1.73M 0.01% 1197
2019
Q2 		– Sell
-97,049
Closed -$4.9M – 3746
2019
Q1 		$4.9M Buy
97,049
+3,789
+4% +$169K 0.02% 971
2018
Q4 		$3.76M Buy
+93,260
New +$4.81M 0.01% 937
2018
Q3 		– Sell
-47,901
Closed -$3.62M – 3685
2018
Q2 		$3.62M Buy
+47,901
New +$3.01M 0.01% 1208
2017
Q1 		– Sell
-33,437
Closed -$2.65M – 3415
2016
Q4 		$2.65M Buy
+33,437
New +$2.43M 0.01% 1273
2016
Q2 		– Sell
-9,300
Closed -$377K – 3308
2016
Q1 		$377K Sell
9,300
-8,924
-49% -$566K ﹤0.01% 2247
2015
Q4 		$1.62M Sell
18,224
-72,646
-80% -$5.74M 0.01% 1204
2015
Q3 		$6.73M Buy
90,870
+48,544
+115% +$4.04M 0.03% 451
2015
Q2 		$3.42M Sell
42,326
-4,679
-10% -$305K 0.02% 907
2015
Q1 		$1.97M Buy
+47,005
New +$1.33M 0.01% 1181

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $984M AUM 72.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $522M AUM 26.29% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $49.3B AUM 36.45% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

John Overdeck's EGRX Position: Q4 2024 in Review

John Overdeck sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 119,312 shares — an estimated $445K sold.

John Overdeck first reported a position in EGRX in Q1 2015 and held it in 19 quarters. The position peaked at $6.73M in Q3 2015. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • John Overdeck reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • John Overdeck sold 119,312 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $445K.
  • John Overdeck first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2015 and held it in 19 quarters.
  • John Overdeck's Eagle Pharmaceuticals, Inc. position peaked at $6.73M in Q3 2015.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on Two Sigma Investments's 13F filing for Q4 2024, filed 14 Feb 2025.